FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 557 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Acalabrutinib June 18, 2025 FDA Approval Likely to Change Initial Treatment for Some People with... May 2, 2025 EMA Recommends Granting a Marketing Authorisation for Akeega, Fixed-Dose Combinations of... March 10, 2023 Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in... April 8, 2022 Load more HOT NEWS FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF... Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve... Breast Cancer May Spread by Recruiting Nearby Sensory Nerves FDA Approves Injectable Nivolumab, an Alternative to IV Infusion
